Ken Griffin Applied Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.35 - $8.5 $97,004 - $189,550	22,300 Added 24.34%	113,900 $968,000
Q2 2024 Aug 14, 2024	SELL	$4.04 - $6.37 $113,120 - $178,360	-28,000 Reduced 23.41%	91,600 $427,000
Q1 2024 May 15, 2024	BUY	$2.25 - $7.4 $123,975 - $407,740	55,100 Added 85.43%	119,600 $813,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $62,560 - $113,900	34,000 Added 111.48%	64,500 $216,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.77 $21,546 - $47,367	17,100 Added 127.61%	30,500 $75,000
Q2 2023 Aug 14, 2023	BUY	$0.77 - $1.8 $10,318 - $24,120	13,400 New	13,400 $17,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $1.12 $7,290 - $15,120	13,500 Added 60.81%	35,700 $27,000
Q3 2022 Nov 14, 2022	BUY	$0.86 - $1.55 $19,092 - $34,410	22,200 New	22,200 $21,000

140

112M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $42.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.